Q-omics provides the consensus-scored SIGLEC31P profile across patient tissues and cancer cell-line models. SIGLEC31P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, SIGLEC31P is differentially expressed in 1, with the highest sampling consensus in KIRP. Additionally, SIGLEC31P RNA expression shows 6,398 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, KIRP, and STAD as cancer lineages where SIGLEC31P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIGLEC31P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIGLEC31P survival associations across molecular data types. SIGLEC31P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIGLEC31P RNA expression–survival associations across cancer types. High SIGLEC31P expression shows unfavorable associations in DLBC, THCA, UCS, UCEC and OV, but favorable associations in BLCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for SIGLEC31P RNA expression.
This table summarizes SIGLEC31P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SIGLEC31P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIGLEC31P shows higher tumor expression in KIRP. The KIRP box plot shows higher SIGLEC31P RNA expression in tumor versus normal tissue (log2 FC = +0.088, t-test p = .023).
This table shows molecular features associated with SIGLEC31P in patient tissues and cancer cell lines. In patient samples, SIGLEC31P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
